Background
==========

The presence of myocardial late gadolinium enhancement (LGE) in patients with sarcoidosis is a powerful predictor of major adverse events (MAE: death, ventricular tachycardia, or appropriate ICD therapy). In this study, we aim to determine if the burden of LGE, left ventricular (LV) and right ventricular (RV) end-diastolic and end-systolic volume index (EDVi & ESVi) and ejection fraction (EF) can be used to improve risk stratification in patients with cardiac sarcoidosis (CS).

Methods
=======

We identified 25 consecutive subjects with a diagnosis of CS (biopsy-proven extra-cardiac sarcoidosis and presence of LGE on cardiovascular magnetic resonance). Imaging was performed on a 1.5T scanner. Short axis cines (6 mm thickness, 4 mm gap, temporal resolution \< 40 ms) spanning the entire LV were acquired to determine LV and RV volumes. Short axis slices were also obtained 10 minutes after contrast (gadodiamide 0.15 mmol/kg) using a phase sensitive inversion recovery reconstruction. LGE was identified on each slice as regions with signal intensity (SI) \> 5 standard deviations above the mean SI of normal remote myocardium. The total amount of LGE as a percentage of LV mass (%LGE) was determined using Diagnosoft Virtue software (Figure [1](#F1){ref-type="fig"}). Medical records were reviewed to identify MAE. Area under the curve (AUC) was determined from receiver-operator characteristics demonstrating the ability of %LGE, LVEDVi, LVESVi, LVEF, RVEDVi, RVESVi, and RVEF to detect MAE. Patients were divided into 2 groups; with MAE and without MAE. Each parameter was evaluated using unpaired T-tests. Continuous variables are presented as mean ± standard deviation.

![**Diagnosoft Virtue software was used to delineate areas of LGE (defined here as having a signal intensity \> 5 standard deviations above that of normal remote myocardium)**.](1532-429X-16-S1-P302-1){#F1}

Results
=======

The mean age was 58 ± 7 years, 18 (72%) were female. Mean follow up was 39 ± 15 months. Six (24%) of patients had MAE. There was a significant difference in %LGE, RVEF and RVESVi but not LVEF, LVESVi, LVEDVi or RVEDVi between those who had MAE and those who did not (Table [1](#T1){ref-type="table"}). The AUC for each of the following parameter\'s ability to predict MAE was: LVEF 0.54, LVEDVi 0.58, LVESVi 0.62, LGE 0.67, RVEDVi 0.76, RVESVi 0.85, and RVEF 0.56. Notably, in terms of predicting death, the AUC for %LGE, RVEDVi and RVESVi were high at 0.87, 0.86 and 0.89 respectively, while that for LVEF was 0.61, RVEF 0.61, LVEDVi 0.54 and LVESVi 0.55.

###### 

Functional and structural parameters for subjects with and without major adverse events

                   MAE +     MAE -     P value
  ---------------- --------- --------- ---------
  LVEF (%)         59 ± 4    60 ± 4    0.53
                                       
  LVEDVi (ml/m2)   65 ± 22   27 ± 9    0.53
                                       
  LVESVi (ml/m2)   27 ± 9    28 ± 7    0.72
                                       
  RVEF (%)         42 ± 12   54 ± 9    0.01
                                       
  RVEDVi (ml/m2)   86 ± 22   72 ± 14   0.09
                                       
  RVESVi (ml/m2)   54 ± 18   34 ± 14   0.007
                                       
  LGE (%)          20 ± 20   7 ± 5     0.01

Conclusions
===========

The burden of LGE and RV size and function (not LV size and function) further improve prediction of death and significant ventricular arrhythmia in patients with cardiac sarcoidosis
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